Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH).
Marta González VicentCristina Díaz de HerediaJesús González de PabloBlanca MolinaAlexandra RegueiroPérez-Martínez AntonioPilar PalomoLucía López CorralEstefanía GarcíaJosé María FernándezAriadna PérezMaría José JiménezManuel GuerreiroCarlos VallejoAna Isabel GallardoOriana LópezAna BenitoJulia MarsalMónica DuarteLeyre BentoIsabel BadellAlexandra PedrazaAna Jiménez UbietoPedro GonzálezIgnacio Gómez CenturiónLissette CostillaCristina BeléndezAlbert EsquirolIldefonso EspigadoEsperanza LavillaMiguel Angel Diaz PerezPublished in: European journal of haematology (2021)
Defibrotide has an acceptable safety profile with an improved response in severe/very severe SOS compared with historical controls, mainly in pediatric patients. Use of defibrotide for prophylaxis may improve prognosis of patients at high risk of complications due to endothelial damage such as those who receive a second transplant. SOS has an important impact on the HSCT long-term survival, as can be concluded from our study.